Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bernell

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Internal Medicine|January 1, 1996
Aplastic anaemia with a trilineage response to erythropoietin therapyP Bernell
Lakartidningen|December 17, 1998
[Genetic origin of malignant hematopoiesis well defined]P Bernell, B Jacobsson
Acta Haematologica Polonica|January 1, 1991
Hematopoietic growth factors for the treatment of myelodysplastic syndromesR Hast, P Bernell
British Journal of Haematology|May 12, 1998
Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphomaP Bernell, L Ohm
Lakartidningen|December 10, 1986
[The man behind the syndrome: Eli Moschkowitz. In hospitals people should be treated, not the disease]P Bernell, P Reizenstein
Leukemia Research|January 1, 1992
Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practiceR Hast, P Bernell
British Journal of Haematology|November 11, 1999
Gain of chromosome 7, which marks the progression from indolent to aggressive follicle centre lymphomas, is restricted to the B-lymphoid cell lineage: a study by FISH in combination with morphology and immunocytochemistryP Bernell, I Arvidsson, B Jacobsson
European Journal of Haematology|July 1, 1987
Possible synergism between cimetidine and interferon in a case of resistant multiple myelomaE Osby, P Bernell, R Hast
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Cimetidine as an immune response modifierR Hast, P Bernell, M Hansson
Cancer Genetics and Cytogenetics|March 1, 1992
Deletion of chromosome 2(p13) is a nonrandomly occurring karyotypic abnormality in myelodysplastic syndromeP Bernell, R Hast, K Bröndum-Nielsen
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Internal Medicine|January 1, 1996
Aplastic anaemia with a trilineage response to erythropoietin therapyP Bernell
Lakartidningen|December 17, 1998
[Genetic origin of malignant hematopoiesis well defined]P Bernell, B Jacobsson
Acta Haematologica Polonica|January 1, 1991
Hematopoietic growth factors for the treatment of myelodysplastic syndromesR Hast, P Bernell
British Journal of Haematology|May 12, 1998
Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphomaP Bernell, L Ohm
Lakartidningen|December 10, 1986
[The man behind the syndrome: Eli Moschkowitz. In hospitals people should be treated, not the disease]P Bernell, P Reizenstein
Leukemia Research|January 1, 1992
Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practiceR Hast, P Bernell
British Journal of Haematology|November 11, 1999
Gain of chromosome 7, which marks the progression from indolent to aggressive follicle centre lymphomas, is restricted to the B-lymphoid cell lineage: a study by FISH in combination with morphology and immunocytochemistryP Bernell, I Arvidsson, B Jacobsson
European Journal of Haematology|July 1, 1987
Possible synergism between cimetidine and interferon in a case of resistant multiple myelomaE Osby, P Bernell, R Hast
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Cimetidine as an immune response modifierR Hast, P Bernell, M Hansson
Cancer Genetics and Cytogenetics|March 1, 1992
Deletion of chromosome 2(p13) is a nonrandomly occurring karyotypic abnormality in myelodysplastic syndromeP Bernell, R Hast, K Bröndum-Nielsen
Pageof 3